Published in J Antimicrob Chemother on January 01, 1993
Mechanisms of high-level resistance to quinolones in urinary tract isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother (1994) 1.60
In vitro activity of Bay y 3118, a new quinolone. Antimicrob Agents Chemother (1993) 1.47
In vitro activity of Bay Y3118 against anaerobic bacteria. Antimicrob Agents Chemother (1993) 1.12
Intracellular penetration and activity of BAY Y 3118 in human polymorphonuclear leukocytes. Antimicrob Agents Chemother (1994) 1.07
Comparative in vitro activities of azithromycin, Bay y 3118, levofloxacin, sparfloxacin, and 11 other oral antimicrobial agents against 194 aerobic and anaerobic bite wound isolates. Antimicrob Agents Chemother (1995) 1.01
Comparative in vitro activity of BAY Y 3118 with other fluoroquinolones. Drugs (1995) 0.78
Antibacterial activities and pharmacokinetics of E-4767 and E-5065, two new 8-chlorofluoroquinolones with a 7-azetidin ring substituent. Antimicrob Agents Chemother (2001) 0.75
In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents. Antimicrob Agents Chemother (1983) 21.48
HR 756, a highly active cephalosporin: comparison with cefazolin and carbenicillin. Antimicrob Agents Chemother (1978) 4.74
LY127935, a novel oxa-beta-lactam: an in vitro comparison with other beta-lactam antibiotics. Antimicrob Agents Chemother (1979) 4.52
Activity of azlocillin and mezlocillin against gram-negative organisms: comparison with other penicillins. Antimicrob Agents Chemother (1978) 3.68
In vitro activity of BAY 12-8039, a new fluoroquinolone. Antimicrob Agents Chemother (1997) 3.22
Local surveillance of antimicrobial resistance. Synercid Resistance Surveillance Group. Lancet (1998) 2.60
In vitro study of clavulanic acid in combination with penicillin, amoxycillin, and carbenicillin. Antimicrob Agents Chemother (1978) 2.58
Comparison of in vitro activity of GR 20263, a novel cephalosporin derivative, with activities of other beta-lactam compounds. Antimicrob Agents Chemother (1980) 2.51
The in-vitro activity of CP 99,219, a new naphthyridone antimicrobial agent: a comparison with fluoroquinolone agents. J Antimicrob Chemother (1995) 2.49
In vitro activity of Ro 15-8074 and Ro 19-5247, two orally administered cephalosporin metabolites. Antimicrob Agents Chemother (1986) 2.45
Comparison of the modified Stokes' method of susceptibility testing with results obtained using MIC methods and British Society of Antimicrobial Chemotherapy breakpoints. J Antimicrob Chemother (1998) 2.42
A reassessment of the in-vitro activity of colistin sulphomethate sodium. J Antimicrob Chemother (1997) 2.37
Clavulanic acid and CP-45,899: a comparison of their in vitro activity in combination with penicillins. J Antimicrob Chemother (1980) 2.35
Low muscle mass and sarcopenia: common and predictive of osteopenia in inflammatory bowel disease. Aliment Pharmacol Ther (2015) 2.34
Azithromycin concentrations at the sites of pulmonary infection. Eur Respir J (1990) 2.33
Comparative pharmacokinetics and tissue penetration of sulbactam and ampicillin after concurrent intravenous administration. Antimicrob Agents Chemother (1982) 2.12
In vitro activity of PD 127,391, an enhanced-spectrum quinolone. Antimicrob Agents Chemother (1988) 2.09
In-vitro activity of sparfloxacin, a new quinolone antimicrobial agent. J Antimicrob Chemother (1990) 2.09
Comparison of the in vitro activity of Bay k 4999 and piperacillin, two new antipseudomonal broad-spectrum penicillins, with other beta-lactam drugs. Antimicrob Agents Chemother (1978) 2.07
In vitro activity of Ro 23-6240, a new difluoroquinolone derivative, compared with that of other antimicrobial agents. Antimicrob Agents Chemother (1986) 2.04
In-vitro activity of enoxacin (CL-919), a new quinoline derivative, compared with that of other antimicrobial agents. J Antimicrob Chemother (1984) 2.01
Lower motor neuron degeneration associated with type C RNA virus infection in mice: neuropathological features. J Neuropathol Exp Neurol (1974) 2.00
Commercially available fluorescein-conjugated monoclonal antibody for determining the in vitro activity of antimicrobial agents against Chlamydia trachomatis. Eur J Clin Microbiol (1987) 1.93
Activity of the cefotaxime (HR756) desacetyl metabolite compared with those of cefotaxime and other cephalosporins. Antimicrob Agents Chemother (1980) 1.87
The comparative pharmacokinetics of five quinolones. J Antimicrob Chemother (1986) 1.86
Bactericidal activity of sparfloxacin and ciprofloxacin under anaerobic conditions. J Antimicrob Chemother (1991) 1.85
Pharmacokinetics and tissue penetration of orally administered lomefloxacin. Antimicrob Agents Chemother (1988) 1.85
In vitro activity of lomefloxacin, a new quinolone antimicrobial agent, in comparison with those of other agents. Antimicrob Agents Chemother (1988) 1.82
The in-vitro activity, pharmacokinetics and tissue penetration of temafloxacin. J Antimicrob Chemother (1989) 1.75
Temocillin, in-vitro activity and the pharmacokinetics and tissue penetration in healthy volunteers. J Antimicrob Chemother (1982) 1.70
Ro 13-9904: A cephalosporin with a high degree of activity and broad antibacterial activity: an invitro comparative study. J Antimicrob Chemother (1980) 1.68
The comparative pharmacokinetics and tissue penetration of single-dose ciprofloxacin 400 mg i.v. and 750 mg po. J Antimicrob Chemother (1994) 1.68
N-formimidoyl-thienamycin a novel beta-lactam: an in-vitro comparison with other beta-lactam antibiotics. J Antimicrob Chemother (1981) 1.65
Pharmacokinetics and tissue penetration of tazobactam administered alone and with piperacillin. Antimicrob Agents Chemother (1991) 1.63
Pharmacokinetics and penetration into inflammatory fluid of trovafloxacin (CP-99,219). Antimicrob Agents Chemother (1996) 1.63
Pharmacokinetics and inflammatory fluid penetration of sparfloxacin. Antimicrob Agents Chemother (1992) 1.62
SQ 26,776, a novel beta-lactam: an in-vitro comparison with other antimicrobial agents. J Antimicrob Chemother (1981) 1.60
The in-vitro activity and tentative breakpoint of gemifloxacin, a new fluoroquinolone. J Antimicrob Chemother (1999) 1.58
Cefixime, in-vitro activity, pharmacokinetics and tissue penetration. J Antimicrob Chemother (1989) 1.57
International collaborative study on standardization of bacterial sensitivity to fosfomycin. J Antimicrob Chemother (1983) 1.52
Pharmacokinetics and inflammatory-fluid penetration of moxifloxacin following oral or intravenous administration. Antimicrob Agents Chemother (1999) 1.50
Ultrastructural studies of multiple sclerosis. Lab Invest (1969) 1.49
Sch 29482--a novel penem antibiotic: an in-vitro comparison of its activity with other beta-lactams. J Antimicrob Chemother (1982) 1.49
Serological characterization of HTLV-III infection in AIDS and related disorders. J Infect Dis (1986) 1.47
Pharmacokinetics and tissue penetration of azthreonam. Antimicrob Agents Chemother (1982) 1.42
Comparison of in vitro activity of FCE 22101, a new penem, with those of other beta-lactam antibiotics. Antimicrob Agents Chemother (1983) 1.42
Pharmacokinetics and inflammatory fluid penetration of intravenous daptomycin in volunteers. Antimicrob Agents Chemother (2002) 1.40
The concentration of sparfloxacin in lung tissues after single and multiple oral doses. Int J Antimicrob Agents (1994) 1.38
Activity of daptomycin against Gram-positive pathogens: a comparison with other agents and the determination of a tentative breakpoint. J Antimicrob Chemother (2001) 1.38
Problems with Iso-Sensitest agar. J Antimicrob Chemother (1990) 1.38
The in-vitro activity of a new highly active quinolone, DU-6859a. J Antimicrob Chemother (1993) 1.38
The in-vitro activity of HMR 3647, a new ketolide antimicrobial agent. J Antimicrob Chemother (1998) 1.37
The in-vitro activity of OPC-17116, a new 5-methyl substituted quinolone. J Antimicrob Chemother (1993) 1.37
Pharmacodynamic properties of HMR 3647, a novel ketolide, on respiratory pathogens, enterococci and Bacteroides fragilis demonstrated by studies of time-kill kinetics and postantibiotic effect. J Antimicrob Chemother (1998) 1.33
Comparison of sensititre dried microtitration trays with a standard agar method for determination of minimum inhibitory concentrations of antimicrobial agents. Antimicrob Agents Chemother (1980) 1.30
Evaluation of the penetration of ciprofloxacin and amoxycillin into the bronchial mucosa. Thorax (1988) 1.29
The in vitro activity of BMS-284756, a new des-fluorinated quinolone. J Antimicrob Chemother (2002) 1.27
In vitro activities of two glycylcyclines. Antimicrob Agents Chemother (1994) 1.27
6-beta-bromo- and 6-beta-iodo penicillanic acid, two novel beta-lactamase inhibitors. J Antimicrob Chemother (1981) 1.27
Open-label crossover study to determine pharmacokinetics and penetration of two dose regimens of levofloxacin into inflammatory fluid. Antimicrob Agents Chemother (1995) 1.25
Comparative bronchoalveolar concentrations of ciprofloxacin and lomefloxacin following oral administration. Respir Med (1993) 1.24
Concentrations of OPC-17116, a new fluoroquinolone antibacterial, in serum and lung compartments. J Antimicrob Chemother (1995) 1.22
Human T-cell lymphotropic virus type 1 Tax mediates enhanced transcription in CD4+ T lymphocytes. J Virol (1996) 1.22
The in-vitro activity of linezolid (U-100766) and tentative breakpoints. J Antimicrob Chemother (1998) 1.22
Pharmacokinetics and tissue penetration of cefpirome, a new cephalosporin. J Antimicrob Chemother (1988) 1.21
In vitro activity of CGP 31608, a new penem. Antimicrob Agents Chemother (1987) 1.21
Pharmacokinetics and tissue penetration of cefepime. J Antimicrob Chemother (1989) 1.19
A study to determine the pharmacokinetics and inflammatory fluid penetration of gatifloxacin following a single oral dose. J Antimicrob Chemother (1999) 1.19
Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. Rev Infect Dis (1988) 1.18
Concentrations of cefixime in bronchial mucosa and sputum after three oral multiple dose regimens. Thorax (1990) 1.18
Microlavage: a technique for determining the volume of epithelial lining fluid. Thorax (1991) 1.18
In vitro activity of L-627, a new carbapenem. Antimicrob Agents Chemother (1992) 1.17
Pharmacokinetics and tissue penetration of rufloxacin, a long acting quinolone antimicrobial agent. J Antimicrob Chemother (1991) 1.16
The in-vitro activity of Ro 17-2301, a new monobactam, compared with other antimicrobial agents. J Antimicrob Chemother (1985) 1.16
Systematic review: IBD-associated pyoderma gangrenosum in the biologic era, the response to therapy. Aliment Pharmacol Ther (2013) 1.15
The pharmacokinetics of the oral cephalosporins--a review. J Antimicrob Chemother (1990) 1.14
In vitro activities of peptide deformylase inhibitors against gram-positive pathogens. Antimicrob Agents Chemother (2002) 1.14
The activity of the methylpiperazinyl fluoroquinolone CG 5501: a comparison with other fluoroquinolones. J Antimicrob Chemother (1997) 1.14
The levels of clarithromycin and its 14-hydroxy metabolite in the lung. Eur Respir J (1994) 1.14
The penetration of cefpirome into the potential sites of pulmonary infection. J Antimicrob Chemother (1991) 1.13
Meropenem pharmacokinetics and penetration into an inflammatory exudate. Antimicrob Agents Chemother (1990) 1.13
Effects of age on concentrations of plasma cholecystokinin, glucagon-like peptide 1, and peptide YY and their relation to appetite and pyloric motility. Am J Clin Nutr (1999) 1.12
The penetration of amoxycillin/clavulanic acid into peritoneal fluid. J Antimicrob Chemother (1983) 1.12
The in-vitro activity of two new quinolones: rufloxacin and MF 961. J Antimicrob Chemother (1992) 1.11
Striatonigral degeneration. Clinical-pathological correlations and response to stereotaxic surgery. Arch Neurol (1970) 1.11
In vitro activity of cefotetan, a new cephamycin derivative, compared with that of other beta-lactam compounds. Antimicrob Agents Chemother (1982) 1.10
Cefoperazone and cefotiam--two new cephalosporins: an in-vitro comparison. J Antimicrob Chemother (1981) 1.10
Juvenile GM2 gangliosidosis. Biochemical and ultrastructural studies on a new variant of Tay-Sachs disease. Arch Neurol (1971) 1.09
The in vitro activity of mezlocillin when combined with cefoxitin or clavulanic acid. J Antimicrob Chemother (1979) 1.09
Pharmacokinetics and inflammatory fluid penetration of clinafloxacin. Antimicrob Agents Chemother (1998) 1.08
Commentary: The association between high dietary intake of docosahexaenoic acid and reduced risk of Crohn's disease. Aliment Pharmacol Ther (2014) 1.07
Altered expression of mucins throughout the colon in ulcerative colitis. Gut (1997) 1.05
Giant-cell ("temporal") arteritis. A disease with variable clinical manifestations. Neurology (1966) 1.04
A chronic care model significantly decreases costs and healthcare utilisation in patients with inflammatory bowel disease. J Crohns Colitis (2011) 1.03
In vitro activity of Bay v 3522, a new cephalosporin, compared with activities of other agents. Antimicrob Agents Chemother (1990) 1.03